GenSight Biologics S.A. | Mutual Funds
Mutual Funds that own GenSight Biologics S.A.
Fidelity Blue Chip Growth Fund
588,530
2.38%
0
0.01%
07/31/2018
AXA Framlington Biotech Fund
514,228
2.08%
514,228
0.19%
02/28/2018
Fidelity Select Biotechnology Portfolio
446,320
1.8%
0
0.01%
07/31/2018
JPMorgan Funds - Global Healthcare Fund
378,179
1.53%
0
0.03%
05/31/2018
Fidelity OTC Portfolio
243,848
0.99%
0
0%
07/31/2018
Fidelity Series Blue Chip Growth Fund
194,511
0.79%
0
0.01%
07/31/2018
Stichting Pensioenfonds ABP (Global Equity Portfolio)
178,571
0.72%
-19,448
0%
03/31/2018
Altitude Profil 100
63,340
0.26%
23,340
0.56%
07/31/2018
Generali Ambition
50,000
0.2%
50,000
0.06%
12/30/2016
40,000
0.16%
0
0.27%
07/31/2018
| Address |
74, rue du Faubourg Saint-Antoine
Paris Ile-de-France 75012
France
|
|
Employees
|
- |
| Website |
http://www.gensight-biologics.com |
| Updated |
07/08/2019 |
| GenSight Biologics SA operates as a biopharmaceutical company, which develops novel therapies for mitochondrial and neurodegenerative diseases for central nervous system based on its proprietary platform technologies that combine gene therapy on mitochondrial targeting and optogenetics. It also provides ophthalmology services, which develops products to restore eyesight to patients suffering from retinal diseases. The company was founded by Bernard Jacques Alex Gilly, Botond Roska, Jean Benn, Luk H. |
